Patents by Inventor Sam Teichman

Sam Teichman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11857595
    Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
    Type: Grant
    Filed: April 15, 2022
    Date of Patent: January 2, 2024
    Assignee: Amryt Endo, Inc.
    Inventors: Roni Mamluk, Sam Teichman
  • Publication number: 20220378867
    Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
    Type: Application
    Filed: August 2, 2022
    Publication date: December 1, 2022
    Inventors: Roni MAMLUK, Sam TEICHMAN
  • Patent number: 11510963
    Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
    Type: Grant
    Filed: August 2, 2022
    Date of Patent: November 29, 2022
    Assignee: Amryt Endo, Inc.
    Inventors: Roni Mamluk, Sam Teichman
  • Publication number: 20220233630
    Abstract: Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
    Type: Application
    Filed: April 15, 2022
    Publication date: July 28, 2022
    Inventors: Roni MAMLUK, Sam Teichman
  • Publication number: 20160287672
    Abstract: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
    Type: Application
    Filed: April 25, 2016
    Publication date: October 6, 2016
    Inventors: Elaine Unemori, Sam Teichman, Thomas Dschietzig, Dennis R. Stewart, Martha Jo Whitehouse
  • Patent number: 9066916
    Abstract: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.
    Type: Grant
    Filed: January 4, 2013
    Date of Patent: June 30, 2015
    Assignee: CORTHERA, INC.
    Inventors: Elaine Unemori, Sam Teichman, Gad Cotter, Dennis Stewart, Martha Jo Whitehouse
  • Publication number: 20140005112
    Abstract: The present disclosure relates to methods for treating human subjects afflicted with chronic heart failure. The methods described herein employ administration of relaxin.
    Type: Application
    Filed: July 11, 2013
    Publication date: January 2, 2014
    Inventors: Elaine Unemori, Sam Teichman, Thomas Dschietzig, Dennis R. Stewart, Martha Jo Whitehouse